In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
|Videos|December 12, 2019
What to Expect in December's Editor-in-Chief Letter
Author(s)Contagion® Editorial Staff
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, previews his editor-in-chief letter for the December issue.
Advertisement
Segment Description: Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, clinical professor at Temple University College of Pharmacy and editor-in-chief of Contagion®, previews his editor-in-chief letter for the December issue.
Interview Transcript (modified slightly for readability):
Gallagher: In my editor-in-chief column in contagion for December, I discuss a law that was recently passed in California allowing pharmacists to dispense PrEP [pre-exposure prophylaxis] and PEP [post-exposure prophylaxis] without a prescription, and what that can mean if it is to go forward and be utilized in other states.
Advertisement
Related to this article
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Advertisement
Advertisement